10x Genomics Inc [TXG] stock is trading at $12.86, down -2.06%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TXG shares have gain 2.14% over the last week, with a monthly amount drifted -4.46%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
10x Genomics Inc [NASDAQ: TXG] stock has seen the most recent analyst activity on September 11, 2025, when Piper Sandler initiated its Neutral rating and assigned the stock a price target of $15. Previously, Leerink Partners downgraded its rating to Market Perform on February 13, 2025, and dropped its price target to $12. On September 03, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $35 on the stock. Jefferies upgraded its rating to a Buy but stick to its price target of $24 on July 22, 2024. JP Morgan downgraded its rating to a Neutral and reduced its price target to $20 on July 18, 2024. Deutsche Bank downgraded its rating to Hold for this stock on July 10, 2024, and downed its price target to $25. In a note dated June 27, 2024, Wolfe Research downgraded an Peer Perform rating on this stock.
10x Genomics Inc [TXG] stock has fluctuated between $6.78 and $24.38 over the past year. Currently, Wall Street analysts expect the stock to reach $14.33 within the next 12 months. 10x Genomics Inc [NASDAQ: TXG] shares were valued at $12.86 at the most recent close of the market. An investor can expect a potential return of 11.43% based on the average TXG price forecast.
Analyzing the TXG fundamentals
10x Genomics Inc [NASDAQ:TXG] reported sales of 644.47M for the trailing twelve months, which represents a growth of 12.93%. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -0.16%, Pretax Profit Margin comes in at -0.12%, and Net Profit Margin reading is -0.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.09, Equity is -0.12 and Total Capital is -0.12. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, 10x Genomics Inc’s Current Ratio is 5.84. Further, the Quick Ratio stands at 5.23, while the Cash Ratio is 3.54. Considering the valuation of this stock, the price to sales ratio is 2.48, the price to book ratio is 2.07.
Transactions by insiders
Recent insider trading involved Saxonov Serge, Chief Executive Officer, that happened on Aug 22 ’25 when 9348.0 shares were sold. Chief Financial Officer, Taich Adam completed a deal on Aug 22 ’25 to sell 22315.0 shares. Meanwhile, Hindson Benjamin J. sold 7486.0 shares on Aug 22 ’25.
